Table 4.

The effect of methotrexate on lipid profiles and cardiovascular risk parameters in male and female psoriatic patients

	Male (n=189, 0W)	Male (n=189, 12W)	Male (0W vs 12W) p-value	Female (n=99,0W)	Female (n=99,12W)	Female (0W vs 12W ) p-value	Male vs female p-value
ApoA1, g/L	1.03 (0.16)	1.00 (0.13)	.0002	1.16 (0.19)	1.14 (0.17)	.1195	<.0001
ApoB, g/L	0.73 (0.17)	0.67 (0.15)	<.0001	0.72 (0.17)	0.69 (0.19)	.0214	.7756
TC, mmol/L	4.68 (0.85)	4.45 (0.83)	<.0001	4.94 (0.98)	4.76 (1.03)	.0083	.0241
TG, mmol/L	1.69 (1.06)	1.68 (1.66)	.1256	1.57 (1.10)	1.50 (1.14)	.1126	.3815
HDL-C, mmol/L	1.14 (0.26)	1.10 (0.23)	.0029	1.37 (0.32)	1.34 (0.31)	.1519	<.0001
LDL, mmol/L	2.94 (0.79)	2.79 (0.74)	.0001	2.95 (0.81)	2.87 (0.89)	.1342	.8775
Lp(a), mg/L	129.6 (148.6)	119.7 (143.9)	.0076	170.1 (195.7)	156.0 (191.8)	.0014	.0399
ApoB:ApoA1 ratio	0.72 (0.19)	0.69 (0.17)	.0001	0.64 (0.17)	0.62 (0.17)	.0762	.0004
TC:HDL-C ratio	4.26 (1.04)	4.18 (1.01)	.0512	3.76 (1.00)	3.68 (0.97)	.234	<.0001
LDL:HDL-C ratio	2.68 (0.84)	2.62 (0.82)	.1057	2.27 (0.77)	2.23 (0.79)	.4272	<.0001
LDL:ApoB ratio	4.04 (0.56)	4.13 (0.56)	.0019	4.09 (0.61)	4.13 (0.64)	.4161	.2722

Abbreviation: ApoA1 apolipoprotein A1, ApoB apolipoprotein B, HC healthy controls, HDL-C high-density lipoprotein-cholesterol, LDL low-density lipoprotein, Lp(a) lipoprotein A, TC total cholesterol, TG triglyceride

Paired t test or Wilcoxon-matched pairs test was used when appropriate. p < .025 is considered to be statistically significant